Tilray | TRLY - Sales Revenues

Stock Price
9.40
Daily Change
0.17 1.84%
Monthly
12.57%
Yearly
1,346.15%
Q2 Forecast
9.04

Tilray reported $217.51M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Acasti Pharma USD -4.76M 4.76M Dec/2024
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Alaunos Therapeutics USD 2K 2K Mar/2025
Aurora Cannabis CAD 94.19M 3.82M Dec/2025
Avita Medical AUD 17.61M 805K Dec/2025
Canopy Growth CAD 74.54M 7.86M Dec/2025
Cronos Group USD 58.39M 22.05M Dec/2025
Dianthus Therapeutics USD 284K 112K Dec/2025
Divis Laboratories Ltd INR 26.04B 1.11B Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
IQVIA Holdings USD 4.36B 260M Dec/2025
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
Moderna USD 678M 342M Dec/2025
Organigram Holdings CAD 63.54M 16.52M Dec/2025
Organon & Co USD 1.51B 90M Dec/2025
Revvity USD 772.06M 73.06M Dec/2025
Tectonic Therapeutic USD 0 0 Dec/2024
Tilray USD 217.51M 74.75M Dec/2025
Viatris USD 3.7B 60M Dec/2025
Xeris Pharmaceuticals USD 85.81M 11.43M Dec/2025
Zealand Pharma A/S 68.91M 19.35M Dec/2025